RxDoctor Payments Data

Jason Poon, MD

Neurology · Kirkland, WANPI 1417319658

Payments from drug & device makers

What this record shows

This record is dominated by grants: $90,000 of the $102,265 with a category attached, or 88.0%. Biogen accounts for 88.0% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2020 at $90,099 and has fallen 95.2% since, to $4,280 in 2025. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$102,265in general payments, 2019–2025

Across 346 payments — averaging $295.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$90K
  • TG Therapeutics, Inc.$4K
  • Novartis$2K
  • EMD Serono, Inc.$1K
  • AbbVie$666
  • Bristol Myers Squibb$607
  • plus $4K from 37 others
$831,608in research payments, 2019–2025

Across 19 payments — averaging $43,769 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$765K
  • TG Therapeutics, Inc.$66K

What the payments were for

  • Consulting fees$3,1083%
  • Grants$90,00088%
  • Food & beverage$9,0739%
  • Education$840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102,265 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$34,647
Medicare patients
108
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab34$331,307
Avonex Pen (4 Pack)Interferon Beta-1a11$91,668
QuliptaAtogepant12$14,715
Dalfampridine ErDalfampridine12$10,659
BrilintaTicagrelor13$5,579
Modafinil16$3,373
Gabapentin90$1,644
Carbamazepine ErCarbamazepine14$807
Baclofen46$730
Duloxetine Hcl25$601
Oxcarbazepine14$450
Levetiracetam24$447
Pregabalin18$387
Nortriptyline Hcl32$385
Tizanidine Hcl18$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$666$14,71512 claims
AstraZenecaBrilinta$20$5,57913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.

Other neurology in Kirkland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →